Predicting Diabetic Macular Edema Treatment Responses Using OCT: Dataset and Methods of APTOS Competition
Weiyi Zhang, Peranut Chotcomwongse, Yinwen Li, Pusheng Xu, Ruijie Yao, Lianhao Zhou, Yuxuan Zhou, Hui Feng, Qiping Zhou, Xinyue Wang, Shoujin Huang, Zihao Jin, Florence H. T. Chung, Shujun Wang, Yalin Zheng, Mingguang He, Danli Shi, Paisan Ruamviboonsuk
TL;DR
This work introduces OCT4DME, a large public OCT dataset paired with the APTOS 2021 Big Data Competition to predict anti-VEGF treatment responses in DME. It details dataset collection, a two-round competition, and multi-task evaluation (IRF/SRF/PED/HRF presence, CST, VA, and CI) using OCT images. Top solutions leverage MIL, weak supervision, and ensemble strategies to achieve high AUC on PED/SRF/IRF detections and meaningful CST/VA predictions, demonstrating AI’s potential to support personalized DME management. The study also discusses data distribution shifts, preprocessing tricks (e.g., gamma transforms), and clinical considerations for deploying AI in ophthalmology, underscoring both the promise and the challenges of clinical translation.
Abstract
Diabetic macular edema (DME) significantly contributes to visual impairment in diabetic patients. Treatment responses to intravitreal therapies vary, highlighting the need for patient stratification to predict therapeutic benefits and enable personalized strategies. To our knowledge, this study is the first to explore pre-treatment stratification for predicting DME treatment responses. To advance this research, we organized the 2nd Asia-Pacific Tele-Ophthalmology Society (APTOS) Big Data Competition in 2021. The competition focused on improving predictive accuracy for anti-VEGF therapy responses using ophthalmic OCT images. We provided a dataset containing tens of thousands of OCT images from 2,000 patients with labels across four sub-tasks. This paper details the competition's structure, dataset, leading methods, and evaluation metrics. The competition attracted strong scientific community participation, with 170 teams initially registering and 41 reaching the final round. The top-performing team achieved an AUC of 80.06%, highlighting the potential of AI in personalized DME treatment and clinical decision-making.
